Breaking News

Cytiva, BioCentriq Awarded NIIMBL Funding to Advance Gene Therapies

Aims to develop new standards that can be used for AAV and advance the development and adoption of gene therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cytiva and BioCentriq, cell and gene therapy contract development and manufacturing organizations (CDMOs), have been awarded funding from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a public-private partnership to accelerate biopharmaceutical innovation.   The project, which is being granted funding as part of NIIMBL’s $15.8 million initiative to drive biotechnology innovation, will involve the creation of a viral and exotoxin clearance platform in an ad...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters